Bevacizumab Biosimilar Market By Product Type ( 100 mg, 400 mg ), By Application ( Colorectal cancer, Lung cancer, Breast cancer, Renal cancers, Brain cancers ), Industry Trends, Estimation & Forecast, 2017 - 2025

April 2018

 Pages: 168

 ERC 2981


Bevacizumab Biosimilar Market is expected to grow with a CAGR of xx% during the forecast period of 2018 to 2025.

Bevacizumab Biosimilar is an improvised monoclonal antibody which is capable of impeding angiogenesis, by blocking the action of vascular endothelial growth factor. Bevacizumab hence, hinders the growth of new blood vessels in tumours. This drug is prescribed for the treatment of various cancers such as lung cancer, breast cancer, glioblastoma, kidney cancer and ovarian cancer. A constant rise in the number of cases of breast cancer as well as lung cancer has developed a serious demand for advanced drugs like bevacizumab all around the world. As per the data revealed by American Cancer Society, breast cancer is the most common cancer diagnosed among U.S. women, with about 252,710 new cases expected to be diagnosed in 2017. This depicts that there is a strong patient base which is present to be targeted by the major drug manufacturers. However, serious side effects such as nose bleeding, rashes, blood pressure hike, gastrointestinal perforation, blood clots and many more might act as a major challenge to the market growth. In addition to this the adoption of other types of drugs such as proto-oncogene and DLBC lymphoma drug might act as an impeding factor for the growth of the very market.

The report provides detailed qualitative and quantitative analysis of the Bevacizumab Biosimilar Market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely product type and application in each of the major regions.

Bevacizumab Biosimilar Market Player Analysis -

The report presents detailed analysis of major players operating in Bevacizumab Biosimilar Market. Few of the include Pfizer, Allergan, Amgen, Biocon, Reliance lifesciences, Bevacizumab, Beaconpharma, Celgene Corporation, Fujifilm Kyowa Kirin Biologics and Hetero Drugs. A detailed coverage on these market players with information on their revenue from bevacizumab biosimilar business, market share, gross margin and their growth strategies have been provided in the report.

Market Segmentation

Bevacizumab Biosimilar market is segmented on the basis of Product Type, Application and Geography. By product type, the market is segmented into 100 mg and 400 mg. On the basis of application, the market is categorized as colorectal cancer, Lung Cancer, Breast Cancer, Renal Cancer and Brain Cancer. Geographical coverage has been provided for each of the major regions including North America, Europe, Asia-Pacific, South America and Rest of the World.

Bevacizumab Biosimilar Market Segmentation

By Product Type
   • 100 mg
   • 400 mg

By Application
   • Colorectal cancer
   • Lung cancer
   • Breast cancer
   • Renal cancers
   • Brain cancers

By Geography
   • North America
             o U.S.
             o Canada
             o Mexico
   • Europe
             o U.K.
             o France
             o Germany
             o Italy
             o Spain
             o Rest of Europe
   • Asia-Pacific
             o China
             o Japan
             o India
             o Korea
             o Rest of APAC
   • South America
             o Brazil
             o Rest of South America
   • Rest of the World
             o Middle East
             o Africa

Bevacizumab Biosimilar Market Key Players

• Pfizer
• Allergan
• Amgen
• Biocon
• Reliance lifesciences
• Bevacizumab
• Beaconpharma
• Celgene Corporation
• Fujifilm Kyowa Kirin Biologics
• Hetero Drugs

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the Bevacizumab Biosimilar Market in 2017 and the expected market size by 2022, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2017 - 2022)?
    • Which are the leading companies in the Bevacizumab Biosimilar Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!